EUVIMEDEUVIMED entdecken
Crossref

Chemotherapy at the End of Life

Semiha Urvay iD, Burak Civelek, Ersin Özaslan, Aziz Ahmet Sürel iD

Journal of Palliative Care · 2021-04 · 36 (2) · 73-77

DOI: 10.1177/0825859720946505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Palliative Care, online erschienen am 06.08.2020. Verfasst von Semiha Urvay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy, Acibadem University Vocational School of Health Services, Istanbul, Turkey. Hauptthemen laut MEDLINE: Neoplasms, Terminal Care. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: The use of chemotherapy at the end of life in advanced cancer patients has increased and end of life care has become increasingly aggressive. The aim of this study is to evaluate patients receiving chemotherapy in the last 3 months of life and the aggressiveness of end-of-life support of these patients.

Methods

All adult patients with solid tumors who received chemotherapy in their last 3 months of life and died in our hospital between January 2015 to June 2019 were included. Detailed information on chemotherapy and toxicity was collected in patient records.

Results

A total of 182 patients included. Median age was 58,9 years. The median survival from the docementation of metastatic disease was 9,98 months (0,95-64,3). Of these 182 patients, 95 (52%) were treated with chemotherapy in the last month of life and 52 (29%) in the last 2 weeks of life. The median number of days between the last administration of chemotherapy and patient death was 29 (0-90). A new chemotherapy regimen was started in the last 3 months of life in 102 patients (56%), in the last month of life in 43 patients (23,6%) and in the last 2 weeks in 23 patients (12.6%). Discussion and Implications: There are many patients who received chemotherapy in the last 3 months of their life and the rates of chemotherapy initiation during this period are well above ideal rates. Whether such care has positive effects on survival or quality of life is questionable and deserves additional investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTerminal CareDeathHumansMiddle AgedPalliative CareQuality of LifeRetrospective Studies

Stichwörter der Autor:innen

cancer/oncologychemotherapydeath and dyingpalliative care

Autor:innen und Institutionen

  • Radiotherapy, Acibadem University Vocational School of Health Services, Istanbul, Turkey.
  • Medical Oncology, Acibadem Kayseri Hospital, Kayseri, Turkey.
  • General Surgery, Ankara City Hospital, Ankara, Turkey.

ORCID-Profile: Semiha Urvay, Aziz Ahmet Sürel

Zitieren

APA

Urvay, S., Civelek, B., Özaslan, E., & Sürel, A. A. (2021). Chemotherapy at the End of Life. Journal of Palliative Care, 36(2), 73-77. https://doi.org/10.1177/0825859720946505

Vancouver

Urvay S, Civelek B, Özaslan E, Sürel AA. Chemotherapy at the End of Life. Journal of Palliative Care. 2021;36(2):73-77. doi:10.1177/0825859720946505

BibTeX
@article{Urvay2021,
  author = {Urvay, Semiha and Civelek, Burak and Özaslan, Ersin and Sürel, Aziz Ahmet},
  title = {Chemotherapy at the End of Life},
  journal = {Journal of Palliative Care},
  year = {2021},
  volume = {36},
  number = {2},
  pages = {73--77},
  doi = {10.1177/0825859720946505}
}
Kostenlos starten →